Intellia Thera CS (NTLA) Stock Price, Quote & News

Company Profile

Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune dis...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 285 6200

Website: www.intelliatx.com

Address:

40 Erie Street, Suite 130, Cambridge, United States

360sage Jun. 25 at 1:33 AM

$NTLA Those who are investing in gene therapy companies, you may want to watch this. $CRSP $BEAM $PRME https://youtu.be/IMpczE6WDzQ

0 · Reply

Bwill15 Jun. 24 at 6:20 PM

$NTLA I love my $NTLA but dang I knew I should have snagged a boat load of $PRME when it was low $1…sad day for me lol

0 · Reply

sogenerous Jun. 24 at 5:13 PM

$NTLA wants 12s soon

1 · Reply

burbs88 Jun. 24 at 2:35 PM

$NTLA Gift of a price. Thank shorts for the set up. This is a multi bagger

0 · Reply

sogenerous Jun. 24 at 1:45 PM

$CRSP $NTLA setting up for big moves imho

0 · Reply

Coplord Jun. 23 at 9:13 PM

$NTLA news?

0 · Reply

Bwill15 Jun. 23 at 8:59 PM

$NTLA can someone confirm that 238,xxx share purchase after hours 🤗

0 · Reply

BigSqueezeComing Jun. 23 at 4:42 PM

$NTLA PT 9.20

0 · Reply

Bwill15 Jun. 23 at 3:49 PM

$NTLA just sold all my position. This thing is going to zero………………………………………………………….JK, ready to buy more if we get into these $8S again! The fluke grade 4 keeping buying levels primed. Two phase three trials, Intellia should be trading around $15. I’ll keep buying until there is a real reason not too besides stock manipulation 🙌

0 · Reply

Letsinvest2024 Jun. 23 at 3:30 PM

$HIMS try $VKTX $NTLA

0 · Reply

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

Jun 5, 2025, 4:01 PM EDT - 19 days ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 29, 2025, 11:25 AM EDT - 26 days ago

Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course

May 20, 2025, 5:47 AM EDT - 5 weeks ago

I Missed The Quantum Rally - I Won't Miss The Next One

AMSC AUTL CAPR CLPT EDIT VANI VERV

May 18, 2025, 7:25 AM EDT - 5 weeks ago

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting

May 14, 2025, 1:57 PM EDT - 5 weeks ago

Intellia Therapeutics, Inc. (NTLA) BofA Securities 2025 Healthcare Conference (Transcript)

May 12, 2025, 9:07 AM EDT - 6 weeks ago

Intellia Therapeutics Shares Have Struggled, But It's Now Go-Time (Rating Upgrade)

May 8, 2025, 11:37 AM EDT - 6 weeks ago

Intellia Therapeutics, Inc. (NTLA) Q1 2025 Earnings Call Transcript

May 5, 2025, 4:44 AM EDT - 7 weeks ago

CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts

CRSP

May 1, 2025, 7:30 AM EDT - 7 weeks ago

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

Apr 23, 2025, 9:50 AM EDT - 2 months ago

Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation

Apr 14, 2025, 10:58 AM EDT - 2 months ago

Final Deadline Today for the Intellia Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - NTLA

Apr 10, 2025, 10:40 AM EDT - 2 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics

Apr 9, 2025, 10:49 AM EDT - 2 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics

Apr 3, 2025, 1:03 PM EDT - 2 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit – NTLA

Apr 3, 2025, 7:30 AM EDT - 2 months ago

Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Mar 28, 2025, 6:24 AM EDT - 3 months ago

Intellia: Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication

Mar 26, 2025, 7:30 AM EDT - 3 months ago

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Mar 11, 2025, 5:43 PM EDT - 3 months ago

Intellia Therapeutics, Inc. (NTLA) Barclays 27th Annual Global Healthcare Conference (Transcript)

Mar 10, 2025, 6:03 PM EDT - 3 months ago

Intellia Therapeutics, Inc. (NTLA) Leerink 2025 Global Biopharma Conference (Transcript)

Mar 6, 2025, 5:45 AM EST - 3 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit - NTLA

Mar 2, 2025, 9:30 AM EST - 4 months ago

Intellia Trades Lower After Q4 Results As Clinical Progress Fails To Impress

Feb 27, 2025, 12:30 PM EST - 4 months ago

Intellia Therapeutics, Inc. (NTLA) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 7:30 AM EST - 4 months ago

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress

Feb 26, 2025, 8:56 PM EST - 4 months ago

Robbins LLP Reminds Intellia Therapeutics, Inc. (NTLA) Investors with Large Losses to Contact the Firm to Learn How They Can Recover for Their Losses

Feb 26, 2025, 1:31 PM EST - 4 months ago

Shareholders of Intellia Therapeutics, Inc. Should Contact The Gross Law Firm Before April 14, 2025 to Discuss Your Rights – NTLA

360sage Jun. 25 at 1:33 AM

$NTLA Those who are investing in gene therapy companies, you may want to watch this. $CRSP $BEAM $PRME https://youtu.be/IMpczE6WDzQ

0 · Reply

Bwill15 Jun. 24 at 6:20 PM

$NTLA I love my $NTLA but dang I knew I should have snagged a boat load of $PRME when it was low $1…sad day for me lol

0 · Reply

sogenerous Jun. 24 at 5:13 PM

$NTLA wants 12s soon

1 · Reply

burbs88 Jun. 24 at 2:35 PM

$NTLA Gift of a price. Thank shorts for the set up. This is a multi bagger

0 · Reply

sogenerous Jun. 24 at 1:45 PM

$CRSP $NTLA setting up for big moves imho

0 · Reply

Coplord Jun. 23 at 9:13 PM

$NTLA news?

0 · Reply

Bwill15 Jun. 23 at 8:59 PM

$NTLA can someone confirm that 238,xxx share purchase after hours 🤗

0 · Reply

BigSqueezeComing Jun. 23 at 4:42 PM

$NTLA PT 9.20

0 · Reply

Bwill15 Jun. 23 at 3:49 PM

0 · Reply

Letsinvest2024 Jun. 23 at 3:30 PM

$HIMS try $VKTX $NTLA

0 · Reply

sogenerous Jun. 23 at 2:19 PM

$NTLA $CRSP I am adding to gene/bio names

0 · Reply

Tomtwitss Jun. 23 at 9:43 AM

$NTLA 9.50

0 · Reply

BigSqueezeComing Jun. 23 at 9:23 AM

$NTLA Intellia Reports Positive 3-Year Lonvo-z Data in HAE Trial at EAACI Congress By Fatima Gulzar | June 23, 2025, 1:41 AM

0 · Reply

Letsinvest2024 Jun. 23 at 1:18 AM

$VKTX $NTLA

0 · Reply

abdullahyim Jun. 22 at 6:31 AM

$NTLA are we done?

2 · Reply

WiseGuyInvestin Jun. 20 at 10:05 PM

$NTLA $ANET $GOOG $ETH.X Ugly day today. Brutal.

0 · Reply

CaveatEmperor Jun. 20 at 5:21 PM

$NTLA added at 9.03

0 · Reply

SignoreRossi Jun. 20 at 4:53 PM

$NTLA A day to add a bunch more

0 · Reply

roger120 Jun. 20 at 3:22 PM

$NTLA verv bo really took out the steam from this group. 8b is only possible if you take the product to market. Watch what happens to $BBIO. I think they end up selling for $20B or going the long road alone. I love your strategy though.

1 · Reply

someguytrades Jun. 20 at 3:09 PM

$NTLA price keeps going down, fair value keeps going up. Bird brains keep selling to buy memes.

0 · Reply

cdewder Jun. 20 at 2:52 PM

$NTLA Anyone have a read on why this is selling off today? I don’t see any filings and there doesn’t seem to be enough open interest expiring today to mean much either way.

2 · Reply

Tomtwitss Jun. 20 at 2:50 PM

$NTLA good gaming strategy.Still holding strong

0 · Reply

Market Cap	956.07M
Revenue (ttm)	57.88M
Net Income (ttm)	-519.02M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-896.72%
Debt to Equity Ratio	0.00

Volume	5,290,400
Avg Vol	4,529,644
Day's Range	N/A - N/A
Shares Out	103.58M
Stochastic %K	62%
Beta	2.15
Analysts	Strong Sell
Price Target	$38.04